Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 14:3:85-96.
doi: 10.1016/j.idm.2018.03.005. eCollection 2018.

Assessing the utility of the tipping point ratio to monitor HIV treatment programmes in the era of universal access to ART

Affiliations

Assessing the utility of the tipping point ratio to monitor HIV treatment programmes in the era of universal access to ART

Simon de Montigny et al. Infect Dis Model. .

Abstract

Background: The epidemiological tipping point ratio (TPR) has been suggested as a useful indicator to monitor the scale-up of antiretroviral treatment (ART) programmes and determine when scale-up is sufficient to control the epidemic. TPR has been defined as the ratio of yearly number of new HIV infections to the yearly number of new ART initiations or to the yearly net increase in the number of people on ART. It has been used to rank the progress of treatment programmes across countries, with the objective of reaching a TPR value under 1. Our study aims to assess if TPR alone can be used as an indicator of ART success across settings by comparing the expected changes in HIV incidence and ART coverage when TPR is maintained constant over time. In particular, we focus on the effect of ART initiation timing (emphasis on ART being initiated early or late during HIV progression) on the interpretation of the TPR.

Methods: We used a dynamic model of HIV transmission in South Africa representing ART rollout leading to universal treatment in 2017. The model is calibrated to HIV incidence, HIV prevalence and ART coverage in 2012 in South Africa, and 1000 simulations are selected for the base-case scenario. To measure the effect of TPR, we simulate TPR-preserving interventions, maintaining TPR (yearly number of new ART initiations denominator) at the value observed in 2019 (between 0.65 and 1.25) for 15 years. We compare ART coverage and HIV incidence across TPR values and across strategies in which ART access is prioritized differently. In a secondary analysis, we illustrate the sensitivity of new ART initiations to ART retention, and we compare both definitions of the TPR.

Results: Our analysis shows that HIV incidence reduction is weakly correlated to TPR: the same reduction in HIV incidence (15%) can be achieved by implementing the same strategy with a wide range of TPR maintained (0.65-1.12). Assuming high retention in ART, TPR-preserving strategies prioritizing early ART initiation yield greater reduction in HIV incidence than strategies where most individuals initiate ART late. High ART coverage is associated with low HIV incidence and it can be reached with a TPR below or equal to one with strategies favoring early ART initiation. Low ART retention over time results in higher HIV incidence even if TPR is maintained low. If ART retention is low, strategies prioritizing late ART initiation are associated with lower HIV incidence than strategies where ART is initiated early. Maintaining a fixed TPR value based on the net increase in people on ART gives higher HIV incidence reduction and requires fast ART scale-up.

Conclusion: Our analysis suggests that the TPR is not an adequate indicator of ART programme impact, without information on ART coverage and retention. Achieving early initiation and adherence to treatment to improve ART coverage might be as important as attaining a specific TPR target. Comparisons of TPR in different settings should account for differences in epidemic conditions.

Keywords: Antiretroviral treatment; HIV; Mathematical modeling; Tipping point.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Compartmental flow diagram of HIV transmission model.
Fig. 2
Fig. 2
Base-case simulations. Temporal dynamics of A) TPR value; B) HIV incidence; C) HIV prevalence and D) ART coverage up to 2034, using the 1000 calibrated simulations, assuming that the ART initiation rates remain unchanged. Highlighted simulations with high TPR (red), balanced TPR (green) and low TPR (blue) have similar HIV incidence in 2019 and are used in the comparison of the impact of TPR-preserving strategies.
Fig. 3
Fig. 3
Correlation between TPR and HIV incidence. Scatterplot of A) TPR vs HIV incidence at the start of the intervention in 2019 (data derived from Fig. 2A and B) and B) TPR vs. HIV incidence reduction achieved at the end of the intervention in 2034, assuming that the “universal first” strategy is implemented (Pearson's r = −0.43). Highlighted simulations with high TPR (red), balanced TPR (green) and low TPR (blue) have similar HIV incidence in 2019 and are used in the comparison of the impact of TPR-preserving strategies.
Fig. 4
Fig. 4
Effect of TPR-preserving strategies on HIV incidence. Expected HIV incidence in 2034. “First” strategies are noted “1st” and “priority” strategies are noted “pri”. HIV incidence in 2019 is 14 new infections per 1000 person-years for all these simulations.
Fig. 5
Fig. 5
Effect of TPR-preserving strategies on ART coverage. A) Effect of ART coverage on HIV incidence. B) Expected ART coverage in 2034 for different TPR-preserving strategies.
Fig. 6
Fig. 6
Comparison between TPR definitions. Scatterplot of average TPR vs HIV incidence in 2024, assuming that the “universal first” strategy is implemented. Green dots represent results using the definition from the main analysis while blue dots represent results using the alternative definition (net TPR) using net ART increase as denominator.)

Similar articles

References

    1. Bass E., de Lacy Donaldson E., Fisher K., Warren M. The tipping Point: Moving from rhetoric to real milestones for ending. AIDS. 2014 http://www.avac.org/sites/default/files/infographics/TippingPointPosterR... Accessed 29-08-16.
    1. Coggin W. 19th core group meeting of the global TB/HIV working group. WHO; 2014. TB/HIV in the Blueprint for an AIDS-free generation.http://www.who.int/tb/challenges/hiv/tb-hiv_in_the_blueprint_for_an_aids... Accessed 1-12-17.
    1. Cohen M.S., Chen Y.Q., McCauley M., Gamble T., Hosseinipour M.C., Kumarasamy N. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine. 2011;365:493–505. - PMC - PubMed
    1. Cori A., Ayles H., Beyers N., Schaap A., Floyd S., Sabapathy K. HPTN 071 (PopART): A cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and Treatment: Mathematical model. PLoS One. 2014;9(1) - PMC - PubMed
    1. Dimitrov D., Kublin J.G., Ramsey S., Corey L. Are clade specific HIV vaccines a necessity? An analysis based on mathematical models. EBioMedicine. 2015;2(12):2062–2069. - PMC - PubMed